Vivotif Typhoid Oral Vaccine

Phase 3Vaccine

UUniversity of Maryland, Baltimore

Vivotif Typhoid Oral Vaccine is one of 41 small molecule programs targeting Vaccine. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VaccineActive, not recruiting

TyphoidRecruiting

SystemicActive, not recruiting

DonorRecruiting

VaccinePhase 1

Active, not recruiting

TyphoidPhase 3

Recruiting

SystemicPhase 3

Active, not recruiting

DonorPhase 3

Recruiting

Competition

Competitive Landscape

36 competitors in Vaccine

#DrugCompanyPhaseTrials

Rotarix ™

GSK

Phase 3

5 2

Havrix

GSK

Phase 3

1 3

Vivotif Typhoid Oral Vaccine

UUniversity of Maryland, Baltimore

Phase 3

1 4

Rotateq

Merck & Co.

Phase 3

3 5

Vaxelis Vaccine

Sanofi

Phase 3

3 6

Varivax

GSK

Phase 3

3 7

M-M-R II Vaccine

Sanofi

Phase 3

2 8

Priorix

GSK

Phase 3

1 9

Trumenba

Pfizer

Phase 3

1 10

Bayer Aspirin

Bayer

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Vaccine

NCT04083950

Q3 2027

Post-ApprovalActive, not recruiting

Systemic

NCT03970304

Q2 2029

ApprovedRecruiting

Typhoid

NCT03705585

Q2 2030

Post-ApprovalRecruiting

Donor

NCT03971669

Clinical

Trials by Indication[1]

Systemic1 trial

CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults

Active, not recruiting·UUniversity of Maryland, Baltimore·Phase 4·NCT03970304·87 enrolled

Donor1 trial

Blood Donor CVD 5000

Recruiting·UUniversity of Maryland, Baltimore·Phase 4·NCT03971669·150 enrolled

Vaccine1 trial

Induction of Gut Permeability by an Oral Vaccine

Active, not recruiting·UUSDA, Western Human Nutrition Research Center·Phase 1·NCT04083950·10 enrolled

Typhoid1 trial

CVD 38000: Immunity, Microbiome, Epigenetics, and a Systems Biology Approach to the Study of Responses to Vaccination With Typhoid and/or Cholera

Recruiting·UUniversity of Maryland, Baltimore·Approved·NCT03705585·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Vivotif Typhoid Oral Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vivotif Typhoid Oral Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vivotif Typhoid Oral Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Maryland, Baltimore

Vivotif Typhoid Oral Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Q2 2029

Q2 2030

Trials by Indication[1]

Systemic1 trial

Donor1 trial

Vaccine1 trial

Typhoid1 trial

References

Drug Info

Quick Facts

Related News